These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35946071)

  • 1. A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members.
    Brito JP; Nagy EV; Singh Ospina N; Zˇarković M; Dosiou C; Fichter N; Lucarelli MJ; Hegedüs L
    Thyroid; 2022 Dec; 32(12):1535-1546. PubMed ID: 35946071
    [No Abstract]   [Full Text] [Related]  

  • 2. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Chinese survey of clinical practice on the management of thyroid eye disease.
    Chen J; Li C; Teng W; Shan Z; Jin J; Wei Y; Sun J; Li Y; Zhou H
    Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
    Krassas GE; Segni M; Wiersinga WM
    Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe.
    Ramos HE; Diehl LA; Camacho CP; Perros P; Graf H;
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):951-6. PubMed ID: 18462263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
    Mohamed A; Tzoulis P; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):979-985. PubMed ID: 36251747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of severe thyroid eye disease: a survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS).
    Perumal B; Meyer DR
    Ophthalmic Plast Reconstr Surg; 2015; 31(2):127-31. PubMed ID: 24988501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
    Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
    Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit.
    Mellington FE; Dayan CM; Dickinson AJ; Hickey JL; MacEwen CJ; McLaren J; Perros P; Rose GE; Uddin J; Vaidya B; Foley P; Lazarus JH; Mitchell A; Ezra DG;
    Orbit; 2017 Jun; 36(3):159-169. PubMed ID: 28296512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.
    Burch HB; Perros P; Bednarczuk T; Cooper DS; Dolman PJ; Leung AM; Mombaerts I; Salvi M; Stan MN
    Thyroid; 2022 Dec; 32(12):1439-1470. PubMed ID: 36480280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How patients experience thyroid eye disease.
    Smith TJ; Hegedüs L; Lesser I; Perros P; Dorris K; Kinrade M; Troy-Ott P; Wuerth L; Nori M
    Front Endocrinol (Lausanne); 2023; 14():1283374. PubMed ID: 38027128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of development of dysthyroid optic neuropathy among individuals with thyroid-eye disease.
    Kemchoknatee P; Thongsawangchai N; Srisombut T; Tangon D; Chantra S
    Eur J Ophthalmol; 2024 May; 34(3):834-842. PubMed ID: 37661652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
    Smith TJ
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent.
    Pradhan A; Ganguly A; Naik MN; Nair AG; Desai S; Rath S
    Indian J Ophthalmol; 2020 Aug; 68(8):1609-1614. PubMed ID: 32709788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
    Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
    Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.